Premium
P2‐299: Oral administration of an apolipoprotein A‐I‐mimetic peptide improves cognitive function and reduces amyloid burden in a mouse model of Alzheimer disease
Author(s) -
Handattu Shaila P.,
Garber David W.,
Monroe Candyce E.,
Groen Thomas,
Kadisha Inga,
Mayakonda Palgunachari,
Li Ling,
Anantharamaiah G.M.
Publication year - 2008
Publication title -
alzheimer's and dementia
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 6.713
H-Index - 118
eISSN - 1552-5279
pISSN - 1552-5260
DOI - 10.1016/j.jalz.2008.05.1375
Subject(s) - morris water navigation task , pravastatin , medicine , lesion , statin , senile plaques , pitavastatin , alzheimer's disease , inflammation , cognitive decline , apolipoprotein e , endocrinology , cholesterol , pathology , disease , dementia , hippocampus
production when boosted once with dual vaccine. In other words, we are investigating the role of pre-existing anti-viral memory Th cells in rapid and efficient generation of anti-A antibody responses in APP/Tg mice. As we suggested, these experiments could simulate the situation in people with early pre-clinical stage AD repeatedly vaccinated/infected with flu virus. Conclusions: Importantly, if successful, dual-vaccine can be used in people with AD at a very early stage that can be diagnosed by measuring tau/A and ptau/A ratio in CSF and/or by screening for accumulation of A in the brains using PIB-PET scan.